John Crane Moves Headquarters to Downtown Chicago (4-Traders)
Duncan Gillis, President and CEO of John Crane said: “Downtown Chicago is a perfect fit for us to expand our corporate headquarters and recruit professional talent. It is a diverse and vibrant city attractive to our employees and also our global customers visiting who will have access to our headquarters and nearby North America manufacturing and service center.” The company, part of global technology business Smiths Group plc (LON:SMIN), employs more than 7,000 people and supplies critical components such as mechanical seals, couplings and bearings, used by energy services customers across oil & gas, power generation, and other major processing industries. John Crane’s 2012 revenues were more than $1.5 billion.
Agency Delays $765 Million in Spending for U.S. Veterans’ Care (BusinessWeek)
The U.S. Department of Veterans Affairs postponed purchases of cardiac monitors, radiological equipment and pain-medication pumps for patients last year. It didn’t replace old surgical tools, oxygen-delivery systems or deteriorating operating-room stretchers. …A VA office in New York, for example, delayed $79,200 in orders for London-based Smiths Group plc (LON:SMIN)’s infusion pumps, used to deliver pain medication for patients, according to the records.
Shire’s Strong-Buy Rating Reaffirmed at Goldman Sachs (SHP) (DailyPolitical)
Shire PLC (LON:SHP)‘s stock had its “strong-buy” rating restated by equities researchers at Goldman Sachs Group, Inc. (NYSE:GS) in a report issued on Tuesday, AnalystRatingsNetwork.com reports. They currently have a GBX 2,675 ($41.03) target price on the stock. Shares of Shire PLC (LON:SHP) opened at 2051.00 on Tuesday. Shire PLC (LON:SHP) has a one year low of GBX 1682.00 and a one year high of GBX 2173.00. The stock’s 50-day moving average is currently GBX 1877.. The company’s market cap is £11.311 billion. …Shire PLC (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
SMC ‘yes’ for Shire’s ADHD drug Elvanse (PharmaTimes)
Children in Scotland with attention-deficit hyperactivity disorder (ADHD) have gained access to a new treatment option after regulators agreed to fund Shire PLC (LON:SHP)’s Elvanse on the National Health Service. The Scottish Medicines Consortium (SMC) has accepted for use Elvanse (lisdexamfetamine dimesylate) as part of a comprehensive treatment programme for the condition in children aged six years and older, when response to previous methylphenidate treatment is inadequate. …According to Shire PLC (LON:SHP), research suggests that 37,000 children and young people are affected by ADHD in Scotland, and yet only 4,539 Scottish children with a diagnosis of ADHD are currently estimated to be in contact with specialist services.
